




		EMLc	ATC codes: <a href="#">L01DA01</a>
Indication	Rhabdomyosarcoma primary site	ICD11 code: <a href="#">2C25.Z</a>	
INN	Dactinomycin		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 500 µg in vial powder for injection		
EML status history	First added in 1984 ( <a href="#">TRS 722</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Tags	<a href="#">Cancer</a>		
Wikipedia	<a href="#">Dactinomycin</a> 		
DrugBank	<a href="#">Dactinomycin</a> 		

## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dactinomycin on the complementary list of the EML and EMLc for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.

[Expert Committee report](#) 

